UCSF has unveiled Nine Square Therapeutics with $50m in series A capital from founding investor Apple Tree Partners.
Nine Square Therapeutics, a US-based movement disorder treatment spinout of University of California, San Francisco (UCSF), has emerged from stealth with a $50m series A commitment from venture firm Apple Tree Partners (ATP), its founding investor.
Nine Square Therapeutics hopes to identify small molecules that assuage movement-related symptoms of neurodegenerative disorders such as Parkinson’s disease as well as non-degenerative indications including essential tremor and dyskinesia.
The spinout will leverage a machine learning-enabled cell profiling technology, combining advances in…
